Friday
night’s HBO “Vice Special Report: Killing Cancer” is a change of pace in
several ways. The topic is less sexy and more universal than the “Vice”
norm, and the approach is straightforward and relatively calm.
With a
little more hedging and a more modulated and dressed-up correspondent,
it could just as well be on “60 Minutes” or PBS.
Mr. Smith points out that the use of H.I.V. and T-cells to fight leukemia by Dr. Carl June at the Children’s Hospital of Philadelphia was first widely publicized in a series of articles in The New York Times, and the “Vice” report can be seen as a wide-ranging and poignant follow-up. Documenting the case of Emily Whitehead (also known as Emma), the first child to receive the experimental treatment, it juxtaposes film of the bald, sad-eyed 6-year-old girl with the currently healthy Emily, still cancer-free more than two years later. Interviewed by Mr. Smith, she concentrates on the charm bracelet she’s stringing, clearly tired of talking about being sick.
The
methods Mr. Smith reports on are only at the clinical-trial stage — Dr.
June speculates that his T-cell therapy might be publicly available by
2016 — and presumably there’s little data so far on relapse rates. Mr.
Smith slips in qualifiers, citing “seemingly miraculous results,” but
he’s clearly a believer, not afraid of using the word “cure.” The
doctors themselves are more cautious — one says, “We know we’re on the
right path” — but still, there are Dr. June’s limited but impressive
results: complete remission in 90 percent of 39 children with leukemia.
Lately, Vice Media has been in the news over a lavish dinner paid for by Mr. Smith as well its metastasizing corporate presence in Williamsburg, Brooklyn.
The return of its television series, which begins a third season next
Friday with more typical topics including the militarization of police
forces and the way gang violence in Central America drives immigration
to the United States, may be a welcome diversion.
Read more: Enlisting Viruses as Commandos in a War on Cancer - NYTimes.com
No comments:
Post a Comment